IMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT) criteria : guidelines of the EU-CARDIOPROTECTION COST Action by the European Union-CARDIOPROTECTION COST ACTION CA16225 & Lecour, Sandrine
Vol.:(0123456789) 
Basic Research in Cardiology          (2021) 116:52  
https://doi.org/10.1007/s00395-021-00893-5
PRACTICAL GUIDELINE
IMproving Preclinical Assessment of Cardioprotective Therapies 
(IMPACT) criteria: guidelines of the EU‑CARDIOPROTECTION COST 
Action
Sandrine Lecour1  · Ioanna Andreadou2  · Hans Erik Bøtker3  · Sean M. Davidson4  · 
Gerd Heusch5 · Marisol Ruiz‑Meana6  · Rainer Schulz7  · Coert J. Zuurbier8  · Péter Ferdinandy9,10  · 
Derek J. Hausenloy4,11,12,13,14  · on behalf of the European Union‑CARDIOPROTECTION COST ACTION CA16225
Received: 19 August 2021 / Revised: 5 September 2021 / Accepted: 6 September 2021 
© The Author(s) 2021
Abstract
Acute myocardial infarction (AMI) and the heart failure (HF) which may follow are among the leading causes of death and 
disability worldwide. As such, new therapeutic interventions are still needed to protect the heart against acute ischemia/
reperfusion injury to reduce myocardial infarct size and prevent the onset of HF in patients presenting with AMI. However, 
the clinical translation of cardioprotective interventions that have proven to be beneficial in preclinical animal studies, has 
been challenging. One likely major reason for this failure to translate cardioprotection into patient benefit is the lack of rig-
orous and systematic in vivo preclinical assessment of the efficacy of promising cardioprotective interventions prior to their 
clinical evaluation. To address this, we propose an in vivo set of step-by-step criteria for IMproving Preclinical Assessment 
of Cardioprotective Therapies (‘IMPACT’), for investigators to consider adopting before embarking on clinical studies, 
the aim of which is to improve the likelihood of translating novel cardioprotective interventions into the clinical setting for 
patient benefit.
Keywords Cardioprotection · Drug development · Ischemia · Reperfusion · Infarction
Introduction
Acute myocardial infarction (AMI) and the heart failure 
(HF) that may follow are among the leading causes of death 
and disability worldwide. For patients presenting with an 
acute ST-segment elevation myocardial infarction (STEMI), 
the treatment priority for limiting myocardial infarct (MI) 
size and preventing the onset of HF, is timely myocardial 
reperfusion by primary percutaneous coronary intervention 
(PPCI). Despite a decline in early mortality, the number of 
STEMI patients going on to develop post-infarct HF remains 
high [34, 36]. As such, there is an urgent need to discover 
novel therapeutic interventions that can be applied as an 
adjunct to PPCI to reduce MI size and prevent post-infarct 
adverse left ventricular (LV) remodelling [19, 20]. However, 
the translation into the clinical setting of novel cardiopro-
tective interventions that have been claimed to be effective 
in experimental animal studies of MI has been extremely 
challenging and largely disappointing, leading to much dis-
cussion in recent literature [5, 10, 17, 18, 21, 23].
Importantly, the endpoints in experimental and clini-
cal studies differ. The most robust primary endpoint in 
experimental studies on cardioprotection is infarct size [3], 
although coronary microvascular injury is also increasingly 
recognized as a manifestation of acute myocardial ischemia/
reperfusion injury (IRI) and thus a target of cardioprotection 
[11, 15, 16]. Although infarct size and coronary microvascu-
lar obstruction are major determinants of patients´ prognosis 
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[7, 35], they are only surrogate endpoints when compared 
to the primary clinical endpoints of mortality and/ or hos-
pitalization for HF. Thus, not only the endpoints per se but 
also the time frame over which these endpoints are assessed 
differ between experimental and clinical studies.
One key reason for the failure to realize cardioprotec-
tion beyond timely coronary revascularization in the clinical 
arena may be the lack of rigorous and systematic pre-clinical 
in vivo efficacy testing of novel cardioprotective interven-
tions, the consequence of which has been the premature 
clinical evaluation of treatments with inconsistent and less-
than-robust cardioprotective effects. To address this, experts 
in the field of cardioprotection and the European Union-
CARDIOPROTECTION COST Action CA16225 [12] have 
joined forces to establish step-by-step criteria for IMprov-
ing Preclinical Assessment of Cardioprotective Therapies 
(IMPACT). We anticipate that adoption of these criteria will 
increase the likelihood of successful clinical translation of 
cardioprotective interventions showing promise in preclini-
cal animal studies.
The focus of the IMPACT criteria will be on the in vivo 
preclinical assessment of efficacy of cardioprotective drugs 
and performance of cardioprotective devices. Safety and 
regulatory issues pertaining to cardioprotective drug and 
device development are beyond the scope of the IMPACT 
criteria and will not be dealt with in this document.
IMPACT criteria for in vivo preclinical 
assessment of cardioprotective 
interventions
To provide a rigorous and systematic approach to the in vivo 
preclinical evaluation of efficacy and performance of novel 
cardioprotective interventions, we propose a step-by-step 
approach for in vivo validation (the IMPACT criteria) in 
both small and large animal models prior to clinical eval-
uation (Fig. 1). Although we appreciate that not all steps 
are relevant for the assessment of both drugs and medical 
devices (given the impact of study costs, complexity, and 
various regulatory requirements), completing more steps is 
likely to correlate with a reduced risk of failure in the clini-
cal translation of novel cardioprotective interventions. For 
each step, we propose the minimum IMPACT criteria that 
need to be met to validate a particular step and the desir-
able IMPACT criteria which, when adhered to, may further 
reduce the risk of translation failure. Finally, in our IMPACT 
criteria, collaborations and the formation of networks 
between research groups are encouraged to improve the 
rigor and reproducibility of in vivo pre-clinical efficacy and 
performance studies evaluating novel cardioprotective inter-
ventions. Published practical general [6, 24, 32] and cardi-
oprotection-specific [3, 28] guidelines or recommendations 
for rigor and reproducibility in preclinical studies should 
be followed together with the current proposed IMPACT 
criteria in the preclinical evaluation of novel cardioprotec-
tive interventions. A summary of the key recommendations 
is shown in Table 1.
Step 1: IMPACT criteria for in vivo validation 
in healthy small animal models
Once a drug or treatment strategy with a medical device has 
been identified to be a potential cardioprotective therapy, the 
first step in the translation pathway is to validate its cardio-
protective efficacy or performance in an in vivo small animal 
model of acute myocardial IRI (Table 2). This validation 
step can be performed using either mouse, rat or rabbit mod-
els, although the use of two of these species or alternatively 
two different strains is desirable to ensure its consistent 
effect across species/strains. At this stage, validation in one 
centre may be sufficient considering that subsequent steps 
will involve multicentre validation. We recommend that the 
MI model should comprise both acute myocardial ischemia 
and reperfusion (rather than permanent occlusion, to bet-
ter represent the clinical scenario) [1], and the endpoint for 
cardioprotection should be infarct size relative to the area-
at-risk (also, consider coronary microvascular obstruction 
as another important endpoint) with a minimum of 2 h of 
reperfusion and preferably 24 h of reperfusion [3]. However, 
measurement of infarct size at 2 h by tetrazolium staining 
may not be as robust as measuring it at 24 h of reperfusion. 
It is desirable to demonstrate benefit of the intervention after 
at least 28 days (by assessing scar size relative to LV mass 
and LV remodelling). We acknowledge that scar size at this 
time-point, LV function and remodelling are confounded by 
other variables beyond infarct size and coronary microvas-
cular obstruction with a longer reperfusion time but this is 
also true in the clinical setting which we wish to predict with 
preclinical data.
Step 1a (desirable): IMPACT criteria for multicentre 
in vivo validation in healthy small animal models
Once the cardioprotective efficacy or performance of the 
cardioprotective intervention has been optimized in a sin-
gle-centre, small animal IRI model, a multicentre validation 
study in a minimum of 3 centres in at least one species (typi-
cally rat or mouse) should strongly be considered to vali-
date study reproducibility (Table 2). This can be achieved 
by independent research centres or by the formation of a 
network of research centres working in partnership to under-
take small animal IRI studies to evaluate the cardioprotective 
intervention in a blinded fashion using standardized proto-
cols and centralized core lab analysis of infarct size and/or 
coronary microvascular obstruction.
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The concept of a multicentre in vivo preclinical evalu-
ation of cardioprotective interventions was first tested in 
2010, with the National Heart, Lung, and Blood Institute 
(NHLBI)-funded, Consortium for preclinicAl assESsment 
of cARdioprotective interventions (CAESAR) research 
network of 3 sites with capabilities for performing acute 
Clinical evaluation of 
cardioprotective therapy
Step 1: Small animal model
IMproving Preclinical Assessment of Cardioprotective Therapies 
(IMPACT) Criteria 
Demonstrate reduction in MI size (and 
possibly also coronary MVO) in aged small 
animal in vivo IRI models with minimum of 
one confounder.
Consider long-term studies with mortality 
and/or heart failure endpoints.
Multicentre validation: Small animal model
Demonstrate reproducibility in at least 3 centres
Multicentre validation: Large animal model
Step 2: Small animal model 
(confounders)
Demonstrate reduction in MI size (and 
possibly also coronary MVO) in large animal 
in vivo IRI model.
Consider long-term studies with mortality 
and/or heart failure endpoints.




























Demonstrate reproducibility in at least 3 centres
Demonstrate reduction in MI size 
(and possibly also coronary MVO) in small 
animal in vivo IRI model.
Consider long-term studies with mortality 
and/or heart failure endpoints
Fig. 1  Overview of IMPACT criteria for improving the preclinical evaluation of novel cardioprotective interventions. IRI ischaemia/reperfusion 
injury, MI myocardial infarct, MVO microvascular obstruction
Table 1  Summary of key recommendations for cardioprotection study design
Study design variable General recommendations for cardioprotection study design
Inclusion and exclusion criteria These must be specified in advance and reported as transparently and as detailed as possible
Sample size This should be determined in advance to required effect size and local data on variability of infarct 
size/coronary microvascular obstruction measurements
Randomization Animals should be randomly allocated to the treatment groups to avoid bias
Blinded treatment allocation and analysis Where possible treatment allocation should be blinded
Study endpoints Infarct size is the gold standard primary endpoint (coronary microvascular obstruction should also be 
considered)
Blinded analysis Infarct size and coronary microvascular obstruction should be assessed in a blinded fashion
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Table 2  IMPACT criteria 
for the in vivo preclinical 
evaluation of efficacy and 
performance of novel 
cardioprotective interventions
Step 1: IMPACT criteria for validation in healthy small animal models
Minimum criteria:
 Validation in one species (e.g.: mouse, rat or rabbit)
 Validation in a single centre
 Acute IRI model (minimum of 2 h and preferably 24 h of reperfusion)
 Infarct size relative to area-at-risk and possibly also coronary microvascular obstruction
Desirable criteria:
 Validation in 2 different species/strains
 Chronic IRI model (at least 28 days of reperfusion)
 Infarct size and LV remodelling (at least 28 days of reperfusion)
Step 1a: IMPACT criteria for multicentre validation in healthy small animal models
Minimum criteria:
 Validation in at least one species
 Validation in at least 3 centres
 Acute IRI model (minimum of 2 h and preferably 24 h of reperfusion)
 Infarct size and possibly also coronary microvascular obstruction
Desirable criteria:
 Validation in 2 different species/strains
 Chronic IRI model (at least 28 days of reperfusion)
 Infarct size and LV remodelling (at least 28 days post-infarction)
Step 2: IMPACT criteria for validation in small animal models with confounders
Minimum criteria:
 Validation in the presence of at least one confounder (e.g. age, diabetes mellitus,  P2Y12 inhibitor)
 Acute IRI model (minimum of 2 h and preferably 24 h of reperfusion)
 Infarct size and possibly also coronary microvascular obstruction
Desirable criteria:
 Validation in both male and female animals
 Validation in the presence of two or more confounders
 Chronic IRI model (at least 28 days of post-infarction)
 Infarct size and LV remodelling (at least 28 days post-infarction)
Step 3: IMPACT criteria for validation in large animal models
Minimum criteria:
 Validation in one species (e.g.: pig)
 Validation in a single centre
 Acute IRI model (minimum of 2 h and preferably 72 h of reperfusion)
 Infarct size and possibly also coronary microvascular obstruction
Desirable criteria:
 Validation in both male and female animals
 Chronic IRI model (at least 3 months post-infarction)
 Infarct size and LV remodelling (at least 3 months post-infarction)
 Assessment in animals with a co-morbidity
Step 3a: IMPACT criteria for multicentre validation in large animal models
Minimum criteria:
 Validation in at least 3 centres
 Acute IRI model (minimum of 2 h and preferably 72 h of reperfusion)
Infarct size and possibly also coronary microvascular obstruction
Desirable criteria:
 Validation in 2 different species/strains
 Chronic IRI model (at least 3 months post-infarction)
 Infarct size and LV remodelling (at least 3 months post-infarction)
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myocardial IRI studies in mice, rabbits and pigs [2, 25, 30, 
34]. The network encompassed the principles of randomiza-
tion, investigator blinding, a priori sample size determina-
tion and exclusion criteria, appropriate statistical analyses, 
assessment of reproducibility, and core lab analysis of his-
tology and biomarkers. Although the CAESAR consortium 
demonstrated cardioprotection with ischemic precondition-
ing [25], it failed to reproduce cardioprotection with phar-
macological agents which had been previously shown to be 
cardioprotective in single-site studies such as nitrite [29] 
and sildenafil [27]. Although the consortium is no longer 
functioning, it illustrates the utility of a multicentre network 
for preclinical evaluation of novel cardioprotective interven-
tions. The EU-CARDIOPROTECTION COST Action [12] 
is currently establishing a small animal research network to 
undertake multicentre, pre-clinical evaluation of novel car-
dioprotective interventions in mice and rat models of acute 
myocardial IRI. Initial validation of the effectiveness of the 
research network will be undertaken using ischemic precon-
ditioning. We propose to utilize a rigorous, standardized, 
multicentre study protocol with a centralized assessment of 
infarct size as described in the NHLBI-CAESAR.
Step 2: IMPACT criteria for in vivo validation in small 
animal model with confounders
A variety of factors have been shown to attenuate the effi-
cacy of cardioprotective interventions in pre-clinical models, 
although the evidence for this occurring in clinical cardio-
protection studies is limited [26]. These confounding fac-
tors include age, sex, and certain co-morbidities (such as 
diabetes, hypertension or dyslipidaemia) and co-medications 
often used during clinical procedures (platelet  P2Y12 inhibi-
tors, heparin, morphine, sedatives, anaesthetics) and more 
chronic care (such as anti-diabetic medications, statins and 
nitrates) are likely to reduce cardioprotective efficacy by 
impacting on intrinsic cardioprotective signalling path-
ways [9]. Therefore, following validation in healthy ani-
mals, step 2 of the IMPACT criteria requires validation in 
a small animal IRI model in the presence of at least one 
of these confounding factors using either a mouse, rat or 
rabbit model with infarct size (and consider also coronary 
microvascular obstruction) at 2–24 h of reperfusion meas-
ured as an endpoint. The choice of confounding factor(s) 
will depend mainly on the mechanism of the intervention 
tested, available resources and facilities but we recommend 
that investigators consider including age, metabolic diseases 
like diabetes or hypercholesterolemia and/or administration 
of a platelet  P2Y12 inhibitor. A useful approach can be to 
use a combination of drugs representing the clinically rel-
evant background drugs typically administered to STEMI 
patients, which has been shown to affect assessment of 
cardioprotective interventions [13]. At this step, desirable 
criteria include testing sex-differences [31], multiple con-
founders and demonstrating cardioprotection after at least 
28 days (in terms of reduced infarct size and less adverse 
LV remodelling).
Step 3: IMPACT criteria for validation in large animal 
model
The penultimate step in the clinical translation pathway is 
the preclinical evaluation of the efficacy of novel cardiopro-
tective interventions in a large animal IRI model. Therefore, 
step 3 of the IMPACT criteria requires validation in a large 
animal model, most often the pig, given its anatomic simi-
larities and the similar temporal and spatial distribution of 
infarction to the human heart [22], in a single centre study 
with infarct size and/or coronary microvascular obstruction 
measured at 2–72 h reperfusion. Desirable criteria include 
demonstrating cardioprotection (in terms of reduced infarct 
size and less adverse LV remodelling) after at least 3 months 
of reperfusion using histology and cardiac MRI [4, 14].
Step 3a (desirable): IMPACT criteria for multicentre 
validation in large animal model
The final step of validation to consider prior to clinical test-
ing of a novel cardioprotective therapy is multicentre vali-
dation using a large animal IRI model, although costs and 
study logistics for such a study are challenging. This valida-
tion (ideally in pigs) should be performed with a minimum 
of 3 centres using a short-term (2–72 h) and/or a long-term 
recovery (at least 3 months) model. It should be undertaken 
according to pre-defined design and protocols, centralized 
randomization and blinded core lab analysis. Where avail-
able the use of both cardiac MRI and histology techniques to 
assess the infarct size and coronary microvascular obstruc-
tion is recommended. In this regard, the CIBERCV (acro-
nym for Spanish network-center for cardiovascular biomedi-
cal research) has set up the "Cardioprotection Large Animal 
Platform" (CIBER-CLAP), a Spanish multicentre network 
of 5 research centres performing acute myocardial IRI in 
pigs for testing the efficacy and reproducibility of novel car-
dioprotective interventions. This network is currently being 
validated using ischemic preconditioning with mechanical 
coronary occlusion/reperfusion as a cardioprotective strat-
egy [33]. Although it is challenging, testing of cardioprotec-
tive drugs in a pig model with co-morbidities would be ideal.
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Future perspectives
The IMPACT criteria have been drawn up to address the 
challenge of translating cardioprotective interventions into 
the clinical setting for patient benefit with a large number of 
neutral clinical cardioprotection studies. These criteria aim 
to improve the rigor and reproducibility of in vivo preclini-
cal efficacy and/or performance studies for cardioprotection, 
by setting out step-by-step criteria required for preclinical 
evaluation of novel cardioprotective interventions in small 
and large animals. The aim of the IMPACT criteria is to 
increase the likelihood of translating cardioprotective inter-
ventions into the clinical setting. Adhesion to these crite-
ria and published guidelines for rigor and reproducibility 
in preclinical studies on cardioprotection [3] will require a 
paradigm shift in the way investigators undertake cardiopro-
tective research. Moreover, in addition to cardioprotective 
efficacy and performance, the evaluation of safety of novel 
cardioprotective drugs and medical devices (not covered in 
this document) will also need to be addressed [8]. Working 
together towards the same hypothesis by sharing expertise, 
knowledge and experimental models is likely to improve 
rigor, reproducibility and increase the chances of translat-
ing cardioprotection for the benefit of patients, although this 
remains to be proven.
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